Bulk IgG Fc glycosylation serves as a biomarker of the inflammatory immune status. Reduced IgG Fc galactosylation and sialylation are associated with systemic inflammation and are commonly observed in patients with inflammatory autoimmune diseases as well as in individuals with hypertrophic adipose tissue.

In contrast, the sialylated IgG subfraction of therapeutic intravenous immunoglobulin (IVIg)—pooled and purified blood serum IgG from healthy donors administered at high doses (2 g/kg) to patients with inflammatory conditions—exhibits potent anti-inflammatory effects.

This project aims to identify plant-derived compounds that can enhance IgG Fc galactosylation and sialylation to reduce inflammatory immune responses.

Building on previous studies that identified a plant compound capable of increasing IgG sialylation, this project conducts a randomised, double-blind, placebo-controlled clinical trial in obese participants.

Following a six-week intervention, blood samples are analyzed to determine whether the compound has improved bulk serum IgG Fc glycosylation and additional inflammatory biomarkers.